Damora Therapeutics (DMRA) Accounts Payables (2019 - 2026)
Damora Therapeutics (DMRA) posted Accounts Payables of $819000.0 for Q1 2026, up 84.46% on a QoQ basis from $444000.0 in Q4 2025, and up 131.36% year-over-year from $354000.0 in Q1 2025.
Damora Therapeutics (DMRA) Accounts Payables (2019 - 2026) Analysis & Trends
Damora Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $819000.0 for Q1 2026.
- Quarterly Accounts Payables rose 131.36% year-over-year to $819000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $819000.0 (up 131.36% YoY) and the FY2025 annual result came in at $444000.0, up 17.77% from the prior year.
- Accounts Payables was $819000.0 for Q1 2026 at Damora Therapeutics, up from $444000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.6 million in Q2 2023 and bottomed at $354000.0 in Q1 2025.
- A 5-year average of $1.9 million and a median of $1.7 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 134.77% — and 2024, when it tumbled 88.76%.
- Damora Therapeutics' Accounts Payables stood at $3.4 million in 2022, then tumbled by 49.19% to $1.7 million in 2023, then plunged by 77.85% to $377000.0 in 2024, then rose by 17.77% to $444000.0 in 2025, then surged by 84.46% to $819000.0 in 2026.
- Business Quant data shows DMRA's Accounts Payables at $819000.0 in Q1 2026, $444000.0 in Q4 2025, and $520000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 819,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 819,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Sep 30, 2025 | 520,000.00 |
| Jun 30, 2025 | 756,000.00 |
| Mar 31, 2025 | 354,000.00 |
| Dec 31, 2024 | 377,000.00 |
| Sep 30, 2024 | 503,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 5.56 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.82 Mn |
| Mar 31, 2022 | 3.22 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | 1.98 Mn |
| Jun 30, 2021 | 1.59 Mn |